CDT Equity (NASDAQ:CDT) Upgraded at Wall Street Zen

Wall Street Zen upgraded shares of CDT Equity (NASDAQ:CDT – Free Report) from a strong sell rating to a sell rating in a research report sent to investors on Saturday morning.

Separately, Weiss Ratings reissued a “sell (e+)” rating on shares of CDT Equity in a report on Wednesday, June 24th. One analyst has rated the stock with a Sell rating, According to MarketBeat, the stock has an average rating of “Sell”.

Get CDT Equity alerts:

Check Out Our Latest Analysis on CDT

CDT Equity Stock Down 2.0%

Shares of CDT opened at $2.87 on Friday. The firm has a market cap of $1.41 million, a price-to-earnings ratio of -0.00 and a beta of 1.52. The company’s fifty day moving average is $6.18 and its 200-day moving average is $93.62. CDT Equity has a 12 month low of $2.53 and a 12 month high of $3,800.00.

CDT Equity (NASDAQ:CDT – Get Free Report) last issued its quarterly earnings data on Wednesday, July 15th. The company reported ($55.60) earnings per share (EPS) for the quarter.

About CDT Equity

(Get Free Report)

Conduit Pharmaceuticals Inc, a clinical-stage specialty biopharmaceutical company, develops pharmaceutical products that provides unmet medical needs in the areas of autoimmune diseases and idiopathic male infertility. Its pipeline includes AZD1656, which has completed Phase I trials for the treatment of type 2 diabetes, renal transplant, Hashimoto's thyroiditis and Grave's disease, uveitis, and preterm labor; and AZD5904, which has completed Phase I clinical trials for the treatment of idiopathic male infertility.

Featured Articles

• Five stocks we like better than CDT Equity
• SpaceX’s First Earnings Report Could Decide Whether Shorts or Bulls Have Control
• Why Rare Earth Processing Could Be the Real 2027 Opportunity
• The S&P 493 Are Staging a Comeback—This Value ETF Offers Broad Exposure
• TSMC Insiders Are Buying the Pullback—But Is the Signal as Bullish as It Looks?

Receive News & Ratings for CDT Equity Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CDT Equity and related companies with MarketBeat.com's FREE daily email newsletter.